On March 2, 2021 Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immune-oncology company accelerating research and development to overcome immune resistance, reported the filing of its interim financial statements and related management’s analysis and discussion for the period ended December 31, 2020 (the third quarterly filings.) These documents are available from SEDAR, the SEC, and the company’s website at www.portagebiotech.com (Press release, Portage Biotech, MAR 2, 2021, View Source [SID1234575914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights for the period and recent weeks are:
• February 25, 2021 – Company’s ordinary shares commence trading on NASDAQ under the symbol PRTG
• February 24, 2021-Company files Form F-3 for a $200 million shelf registration statement;
• February 11, 2021 – Company issues Research & Development update and 2021 plans to advance three clinical trial assets in its pipeline

"Filing the shelf registration statement is an important step as we look to drive value for our stakeholders," said Allan Shaw, chief financial officer of Portage Biotech. This is part of our plan to obtain the capital needed to effectively accelerate and execute our developmental activities and continue to advance our portfolio of platforms with unique mechanisms of action for the immune-oncology market from discovery to the clinic.